About

Shield Therapeutics is a high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.

Explore section

Lead Products

Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. In this section you can learn more about our lead product, and about our second asset.

Explore section

Investors

Shield is well positioned to become a fast growing, independent, international specialty pharmaceutical company due to the strength of its products and team, and with great thanks to all of our supportive shareholders.

Explore section

Careers

As a unified team we are constantly driven by and committed to our goals, seeking to deliver them with transparency and respect. Being consistent to this vision, while enjoying the journey, has brought us to where we are today.

Explore section

All jobs

Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement.

19 Sep 2018

Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement for the commercialisation of Feraccru® in Europe, Australia and New Zealand.

For further details see the attachment below.

STX_Exclusive Licence Agreement

Back to news

Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement.

Sign up for news